Brickell Biotech
2600 SW 3rd Avenue, Suite 350
Miami
Florida
33129
United States
Website: http://www.brickellbio.com/
Email: info@brickellbio.com
85 articles about Brickell Biotech
-
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics
9/7/2022
Brickell Biotech, Inc. announced that it has changed its name to Fresh Tracks Therapeutics, Inc.
-
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/11/2022
Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022
8/2/2022
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th.
-
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
7/20/2022
Brickell Biotech, Inc. today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement.
-
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
7/6/2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that its management team will participate in a fireside chat at the upcoming William Blair Biotech Focus Conference 2022.
-
Brickell Biotech Announces 1-For-45 Reverse Stock Split
7/1/2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), today announced that at the special meeting of stockholders held on June 30, 2022, the Company’s stockholders approved a reverse stock split of the Company's common stock at a ratio between 1-to-10 and 1-to-45, as determined by the Board of Directors of the Company.
-
Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/12/2022
Brickell Biotech, Inc. announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022
5/5/2022
Brickell Biotech, Inc. announced that it will report its first quarter financial results on Thursday, May 12th.
-
Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
5/3/2022
Brickell Biotech, Inc. announced that it has signed and closed a definitive asset purchase agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, whereby Botanix has acquired the Company’s rights to sofpironium bromide, a retrometabolically-designed new chemical entity that belongs to a class of medications called anticholinergics.
-
Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders
5/3/2022
Brickell Biotech, Inc. announced that its 2022 annual meeting of stockholders has been adjourned to Tuesday, May 17, 2022 at 10 a.m. Mountain Time with respect to all proposals described in Brickell’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 22, 2022.
-
Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/15/2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting
3/10/2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), announced today that results from the US Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients were selected for an oral presentation at the Late-Breaking Research session during the American Academy of Dermatology’s (AAD) 2022 Annual Meeting.
-
Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022
3/8/2022
Brickell Biotech, Inc. announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15th.
-
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
-
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences
2/2/2022
Brickell Biotech, Inc. today announced that they have entered into a licensing agreement, whereby Brickell will have the exclusive, worldwide rights to develop and commercialize Carna’s portfolio of novel, potent, and orally available Stimulator of Interferon Genes (STING) antagonists.
-
Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/9/2021
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021
11/1/2021
Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced that it will report its financial results for the third quarter, ended September 30, 2021.
-
Brickell Biotech Prices Public Offering of Common Stock
10/28/2021
Brickell Biotech, Inc. announced today the pricing of its previously announced underwritten public offering of 26,316,000 shares of its common stock at a price to the public of $0.38 per share.
-
Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock
10/27/2021
Brickell Biotech, Inc. announced today that it has commenced a proposed underwritten public offering of shares of its common stock.